These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24701967)

  • 1. Buprenorphine Treatment for Probationers and Parolees.
    Gordon MS; Kinlock TW; Schwartz RP; Couvillion KA; Sudec LJ; O'Grady KE; Vocci FJ; Shabazz H
    Subst Abus; 2015; 36(2):217-25. PubMed ID: 24701967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.
    Gordon MS; Vocci FJ; Taxman F; Fishman M; Sharma B; Blue TR; O'Grady KE
    Contemp Clin Trials; 2019 Apr; 79():21-27. PubMed ID: 30797042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.
    Mitchell SG; Gryczynski J; Kelly SM; O'Grady KE; Jaffe JH; Olsen YK; Schwartz RP
    J Drug Issues; 2014 Jan; 44(1):69-82. PubMed ID: 25364037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment.
    Kelly SM; Oʼgrady KE; Jaffe JH; Gandhi D; Schwartz RP
    J Addict Med; 2013; 7(2):133-8. PubMed ID: 23455877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy for opioid addiction in community corrections.
    Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
    Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
    Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
    J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
    Soyka M; Strehle J; Rehm J; Bühringer G; Wittchen HU
    Eur Addict Res; 2017; 23(2):97-105. PubMed ID: 28376505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
    Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
    Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
    Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
    Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
    Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
    Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine to treat opioid use disorder: A practical guide.
    Nissly T; Levy R
    J Fam Pract; 2018 Jun; 67(9):544-548. PubMed ID: 30216393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
    Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
    J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
    Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
    Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.